FDA Approves StemCyte’s REGENECYTE™ Cord Blood Therapy

Help Spread The Word, Share Post:

StemCyte Inc. announced FDA approval of its REGENECYTE™ cord blood stem cell therapy for treating blood and immune system disorders, making them the first U.S.-based biotech company to receive such a biologics license for this therapy in 2024.

REGENECYTE™ is an allogeneic therapy derived from umbilical cord blood.

The company is also exploring other applications for its cord blood products, including treating long COVID and stroke, and plans to be listed on the Taipei Stock Exchange in December 2024.

StemCyte boasts one of the world’s largest cord blood stem cell inventories and is committed to advancing regenerative medicine.

Find out more in our latest podcast episode below:

*** All content on NationalStemCellTherapy.com is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.

*** Our website contains affiliate advertisements. We may receive a commission for purchases made through these ads at no additional cost to you.

FDA Approves StemCyte’s REGENECYTE™ Cord Blood Therapy

Help Spread The Word, Share Post:

Stay Connected

More Updates